Equities analysts expect that MEI Pharma, Inc. (NASDAQ:MEIP) will report earnings of ($0.07) per share for the current quarter, according to Zacks. Three analysts have issued estimates for MEI Pharma’s earnings. MEI Pharma posted earnings per share of ($0.15) during the same quarter last year, which would indicate a positive year over year growth rate of 53.3%. The firm is scheduled to announce its next quarterly earnings report on Thursday, February 4th.
On average, analysts expect that MEI Pharma will report full-year earnings of ($0.51) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.42). For the next financial year, analysts expect that the company will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.79) to ($0.26). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for MEI Pharma.
MEI Pharma (NASDAQ:MEIP) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.18). MEI Pharma had a negative net margin of 142.81% and a negative return on equity of 33.55%. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $2.48 million.
NASDAQ MEIP opened at $2.64 on Wednesday. The company’s fifty day moving average price is $2.87 and its two-hundred day moving average price is $3.04. MEI Pharma has a 12 month low of $0.72 and a 12 month high of $4.46. The company has a market capitalization of $297.06 million, a price-to-earnings ratio of -4.40 and a beta of 1.71.
Several large investors have recently made changes to their positions in the company. Bank of Montreal Can bought a new position in shares of MEI Pharma in the 2nd quarter worth $28,000. State of Wisconsin Investment Board purchased a new stake in MEI Pharma in the 2nd quarter worth approximately $44,000. Brooks Moore & Associates Inc. bought a new stake in MEI Pharma during the 3rd quarter worth approximately $34,000. Private Advisor Group LLC purchased a new position in MEI Pharma during the second quarter valued at approximately $53,000. Finally, HighMark Wealth Management LLC bought a new position in shares of MEI Pharma in the third quarter worth approximately $52,000. 54.58% of the stock is currently owned by institutional investors.
MEI Pharma Company Profile
MEI Pharma, Inc, a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.
Featured Article: Dual Listing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.